 |
2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate |
|---|---|
| Trade Name | |
| Orphan Indication | Patients with Frederickson Type I or V hyperlipoproteinemia |
| USA Market Approval | USA |
| USA Designation Date | 2015-04-15 00:00:00 |
| Sponsor | CymaBay Therapeutics, Inc.;7999 Gateway Blvd, Suite 130;Newark, California, 94560 |
